Skip to main content

Table 1 Baseline characteristic of patients

From: Statins and clinical outcomes in hospitalized COVID-19 patients with and without Diabetes Mellitus: a retrospective cohort study with propensity score matching

  

Unmatched

Propensity score matched

Characteristic

Cohort (n = 922)

Inpatient Statin (n = 250)

Non Statin (n = 672)

p-value

Inpatient Statin (n = 229)

Non Statin (n = 229)

p-value

Age, (years) n (%)

 Median (IQR)

66 (56–73.25)

66 (59–75)

65 (54–73)

0.007

66 (58.5–75)

68 (59–75)

0.49

 18–30

26 (2.8)

0

26 (3.9)

0

5 (2.2)

 31–45

81 (8.8)

10 (4)

71 (10.6)

8 (3.5)

20 (8.7)

 46–64

320 (34.7)

91 (36.4)

229 (34.1)

87 (38)

63 (27.5)

 ≥ 65

495 (53.7)

149 (59.6)

346 (51.5)

134 (58.5)

141 (61.6)

Sex, n (%)

 Male

490 (53.1)

139 (55.6)

351 (52.2)

0.36

123 (53.7)

128 (55.9)

0.64

 Female

432 (46.9)

111 (44.4)

321 (47.8)

106 (46.3)

101 (44.1)

Race, n (%)

 Blacks

688 (74.6)

179 (71.6)

509 (75.7)

0.2

167 (72.9)

172 (75.1)

0.59

 Other races

234 (25.4)

71 (28.4)

163 (24.3)

62 (27.1)

57 (24.9)

BMI

 Median (IQR)

29.4 (25.2–35.9)

29.25 (24.4–34.83)

29.4 (25.6–36.5)

0.17

29.7 (24.9–35.1)

29.27 (25.65–35.35)

0.78

 < 18.5 (underweight)

28 (3)

8 (3.2)

20 (3)

6 (2.6)

8 (3.5)

 18.5–24.9 (normal)

195 (21.1)

65 (26)

130 (19.3)

53 (23.1)

44 (19.2)

 25–29.9 (overweight)

266 (28.9)

61 (24.4)

205 (30.5)

57 (24.9)

73 (31.9)

 ≥ 30 (obese)

432 (46.9)

116 (46.4)

316 (47)

113 (49.3)

104 (45.4)

Comorbidities, n (%)

 Preexisting lung diseases

304 (33)

87 (34.8)

217 (32.3)

0.47

81 (35.4)

74 (32.3)

0.49

 Coronary artery disease

214 (23.2)

94 (37.6)

120 (17.9)

 < 0.001

86 (37.6)

76 (33.2)

0.33

 Hypertension

756 (82)

233 (93.2)

523 (77.8)

 < 0.001

213 (93)

200 (87.3)

0.04

 Diabetes Mellitus

413 (44.8)

136 (54.4)

277 (41.2)

 < 0.001

126 (55)

119 (52)

0.51

 Hyperlipidemia

280 (30.4)

127 (50.8)

153 (22.8)

 < 0.001

109 (47.6)

101 (44.1)

0.45

 Congestive Heart Failure

135 (14.6)

56 (22.4)

79 (11.8)

 < 0.001

51 (22.3)

46 (20.1)

0.57

 Stroke

100 (10.8)

48 (19.2)

52 (7.7)

 < 0.001

39 (17)

37 (16.2)

0.8

 Cancer

88 (9.5)

18 (7.2)

70 (10.4)

0.14

18 (7.9)

16 (7)

0.72

 Chronic liver disease

35 (3.8)

3 (1.2)

32 (4.8)

0.01

3 (1.3)

5 (2.2)

0.48

 Chronic kidney disease

110 (11.9)

41 (16.4)

69 (10.3)

0.01

36 (15.7)

37 (16.2)

0.9

 ESRD on dialysis

98 (10.6)

31 (12.4)

67 (10)

0.29

30 (13.1)

20 (8.8)

0.13

 Smoking

387 (42)

117 (46.8)

270 (40.2)

0.07

103 (45)

112 (48.9)

0.4

Insurance

 Uninsured

9 (1)

3 (1.2)

6 (0.9)

0.03

3 (1.3)

4 (1.7)

0.83

 Medicaid

242 (26.2)

52 (20.8)

190 (28.3)

50 (21.8)

45 (19.7)

 Medicare

595 (64.5)

180 (72)

415 (61.8)

161 (70.3)

168 (73.4)

 Private

76 (8.2)

15 (6)

61 (9.1)

15 (6.6)

12 (5.2)

Days from symptom onset to hospital presentation

 0–5

649 (70.4)

185 (74)

464 (69)

0.2

173 (75.5)

168 (73.4)

0.78

 6–10

160 (917.4)

39 (15.6)

121 (18)

39 (17)

39 (17)

 11–15

55 (6)

10 (4)

45 (6.7)

10 (4.4)

15 (6.6)

 16 + 

18 (2)

7 (2.8)

11 (1.6)

7 (3.1)

7 (3.1)

CURB-65 at presentation

 0

222 (24.1)

36 (14.4)

186 (27.7)

 < 0.001

35 (15.3)

44 (19.2)

0.44

 1

280 (30.4)

81 (32.4)

199 (29.6)

76 (33.2)

62 (27.1)

 2

275 (29.8)

88 (35.2)

187 (27.8)

82 (35.8)

80 (34.9)

 3

110 (11.9)

38 (15.2)

72 (10.7)

30 (13.1)

32 (14)

 4

20 (2.2)

4 (1.6)

16 (2.4)

3 (1.3)

8 (3.5)

 5

12 (1.3)

3 (1.2)

9 (1.3)

3 (1.3)

3 91.3)